Abstract
Rivaroxaban is one of the new anti-coagulants that inhibit Factor Xa and rarely cause rectus sheath hematoma and retroperitoneal haemorrhage which are uncommon, life-threatening complications. Here is a case of an elderly patient on rivaroxaban therapy for the stroke prevention in non-valvular atrial fibrillation who developed rectus sheath hematoma and retroperitoneal bleeding.
Author supplied keywords
Cite
CITATION STYLE
APA
Börekci, E. (2019). Rectus sheath hematoma and retroperitoneal bleeding due to rivaroxaban: A case report. African Health Sciences, 19(2), 2290–2293. https://doi.org/10.4314/ahs.v19i2.55
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free